Close this search box.

DC5 co-supervisor

Dr. Michael Morris

Waters (legal name: Micromass UK Ltd.) (WATERS), MS Research , United Kingdom

Mike received his B.Sc. (Hons) in Analytical Chemistry from UMIST, Manchester in 1985, and a Ph.D. in mass spectrometry from the same institution in 1988. He undertook academic positions in Japan (Osaka University), USA (Purdue University) and Canada (National Research Council) before joining Micromass/Waters in the R&D department in 1994.

He founded the Clinical Operations Group in Waters in 1999 and was responsible for the development of applications of mass spectrometry in neonatal screening, therapeutic drug monitoring and clinical toxicology.

He rejoined the mass spectrometry research team in 2010 and maintains a keen interest in the uses of mass spectrometry – particularly in the health sciences.

Mike has been the co-organiser of a number of national and international scientific meetings, has co-authored more than 65 publications, contributed to two Clinical and Laboratory Standards Institute (CLSI) guidance documents and is a named inventor on 24 granted US patents. He is also a Chartered Chemist and Fellow of the Royal Society of Chemistry (C.Chem., F.R.S.C.), currently sits on the Executive Committee of UK Community for Analytical Measurement Science, is a member of the Advisory Board for the Departments of Chemistry at the Universities of Reading and Manchester, and is a member of the Chemical and Biological Metrology Committee for the UK National Measurement Institute.

“The combination of the techniques of mass spectrometry (MS) and ion mobility (IM) can give great insight into the analysis of complex mixtures, and the structures of the individual components of those mixtures.

The focus of MobiliTraiN is to bring the different approaches that have been used by researchers into a consensus approach from which research teams with less experience can benefit.

It is particularly relevant that the main commercial protagonists of the IM/MS instrumentation are supporting this project across the EU.”

Selected Publications

  1. H Krenkel, J Brown, K Richardson, E Hoyes, M Morris and R Cramer, Ultrahigh-throughput Sample Analysis using Liquid Atmospheric Pressure Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry, Anal. Chem., 94 (2022) 4141-4145. doi: 10.1021/acs.analchem.1c05614
  2. B N Green, The Analysis of Human Haemoglobin Variant using Mass Spectrometry, edited by M R Morris and J P Williams, Waters Corporation (2021). ISBN 978-1-5262-0895-8.
  3. C Eldrid, J Ujma, S Kalfas, N Tomczyk, K Giles, M Morris and K Thalassinos, Gas Phase Stability of Protein Ions in a Cyclic Ion Mobility Spectrometry Traveling Wave Device, Anal. Chem., 91 (2019) 7554-7561. doi: 10.1021//acs.analchem.6b01705
  4. I Sinclair ,M Bachman, D Addison, M Rohman, D C Murray, G Davies, E Mouchet, M E Tonge, R G Stearns, L Ghislian, S S Datwani, L Majlof, E Hall, G R Jones, E Hoyes, J Olechno, R N Ellson, P E Barran, S D Pringle, M R Morris and J Wingfield, Acoustic Mist Ionisation Platform for Direct and Contactless Ultrahigh-Throughput Mass Spectrometry Analysis of Liquid Samples, Anal. Chem., 91 (2019) 3790-3794. doi: 10.1021/acs.analchem.9b00142
  5. J Ujma, K Giles, M Morris and P E Barran, New High Resolution Ion Mobility Mass Spectrometer Capable of Measurements of Collision Cross Sections from 150 to 520K, Anal.Chem., 88 (2016) 9469-9478. 10.1021/acs.analchem.6b01812
  6. E Jurneczko, F Cruickshank, M Porrini, P Nikolova, I D G Campuzano, M Morris, P E Barran, Intrinsic disorder in proteins: a challenge for (un) structural biology met by ion mobilitymass spectrometry, Biochem. Soc. Trans., 40 (2012) 1021-1026. doi: 10.1042/BST20120125
  7. C Rossi, L Calton, G Hammond, H A Brown, A M Wallace, P Sachetta and M Morris, Serum Steroid Profiling for Congenital Adrenal Hyperplasia using Liquid Chromatography – Tandem Mass Spectrometry, Clin. Chim. Acta, 411 (2010) 222-228. doi: 10.1016/j.cca.2009.11.007
  8. D H Chace, J R Barr, M W Duncan, D Matern, M R Morris, D E Palmer-Toy, A L Rockwood, A Urbani and A L Yergey, CLSI Mass Spectrometry in the Clinical Laboratory: General Principles and Guidance; Approved Guideline. CLSI document C50-A, Wayne, PA: Clinical and Laboratory Standards Institute.
  9. P J Taylor, S R Brown, D P Cooper, P Salm, M R Morris, P I Pillans and S V Lynch, Evaluation of three internal standards for the measurement of Cyclosporin by HPLC – mass spectrometry, Clin. Chem., 51 (2005) 1890. doi: 10.1373/clinchem.2005.055160
  10. K Mills, A Vellodi, P Morris, D Cooper, M Morris, E Young and B Winchester, Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry Disease, Eur. J. Pediatr., 163 (2004) 595-603. doi: 10.1007/s00431-004-1484-z
  11. B G Keevil, D P Tierney, D P Cooper, M R Morris, A Machaal and N Yonan, Simultaneous and Rapid Analysis of Cyclosporin A and Creatinine in Finger Prick Blood Samples using Liquid Chromatography Tandem Mass Spectrometry and its Application in C2 Monitoring, Ther. Drug Mon., 24 (2002)  757-767.
  12. I Mushtaq, S Logan, M Morris, A W Johnson, A M Wade, D Kelly and P T Clayton, Screening of newborn infants for cholestatic hepatobiliary disease with tandem mass spectrometry, Br. Med. J., 319 (1999) 471-477. doi: 10.1136/bmj.319.7208.471